Identification of quinoxalin-2(1H)-one Derivatives as a Novel Class of Multifunctional Aldose Reductase Inhibitors

References

• WHO . Disease Action Now Booklet (2011). www.who/diabetes/pubs/pdf/ndfs.pdf
   Google Scholar
• Guariguata L , WhitingD, WeilC, UnwinN. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res. Clin. Pract.94(3), 322–332 (2011).
   PubMed Web of Science ®Google Scholar
• Nathan DM . Long-term complications of diabetes mellitus. N. Engl. J. Med.328(23), 1676–1685 (1993).
   PubMed Web of Science ®Google Scholar
• Kao YL , DonaghueK, ChanA, KnightJ, SilinkM. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes48(6), 1338–1340 (1999).
   PubMed Web of Science ®Google Scholar
• Alexiou P , PegklidouK, ChatzopoulouM, NicolaouI, DemopoulosVJ. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr. Med. Chem.16(6), 734–752 (2009).
   PubMed Web of Science ®Google Scholar
• Hers HG . The mechanism of the transformation of glucose in fructose in the seminal vesicles. Biochim. Biophys. Acta22(1), 202–203 (1956).
   PubMedGoogle Scholar
• Suzen S , BuyukbingolE. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem.10(15), 1329–1352 (2003).
   PubMed Web of Science ®Google Scholar
• Gabbay KH , MerolaLO, FieldRA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science151(3707), 209–210 (1966).
   PubMed Web of Science ®Google Scholar
• Brownlee M . Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Jin HK , NishimuraC. The involvement of aldose reductase in diabetic complications. Diabetes Metab. Rev.4(4), 323–337 (1988).
   PubMedGoogle Scholar
• Chung SS , ChungSK. Genetic analysis of aldose reductase in diabetic complications. Curr. Med. Chem.10(15), 1375–1387 (2003).
   PubMed Web of Science ®Google Scholar
• Yabenishimura C . Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev.50(1), 21–33 (1998).
   PubMed Web of Science ®Google Scholar
• Heyningen RV . Formation of polyols by the lens of the rat with ‘sugar’ cataract. Nature184(4681), 194–195 (1959).
   Web of Science ®Google Scholar
• Grimshaw CE , LaiCJ. Oxidized aldose reductase: in vivo factor, not in vitro artifact. Arch. Biochem. Biophys.327(1), 89–97 (1996).
   PubMed Web of Science ®Google Scholar
• Srivastava SK , RamanaKV, BhatnagarA. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev.26(3), 380–392 (2005).
   PubMed Web of Science ®Google Scholar
• Ramana KV , SrivastavaSK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell Biol.42(1), 17–20 (2010).
   PubMed Web of Science ®Google Scholar
• Cappiello M , VoltarelliM, CecconiIet al. Specifically targeted modification of human aldose reductase by physiological disulfides. J. Biol. Chem.271(52), 33539–33544 (1996).
   PubMed Web of Science ®Google Scholar
• El-Kabbani O , DarmaninC, SchneiderTRet al. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: implications for the binding of cyclic imide inhibitors. Proteins55(4), 805–813 (2004).
   PubMed Web of Science ®Google Scholar
• Maritim AC , SandersRA, IiiJBW. Effects of α-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats. J. Nutr. Biochem14(5), 288–294 (2003).
   PubMed Web of Science ®Google Scholar
• Rui HL , HotchkissJH. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat. Res339(2), 73–89 (1995).
   PubMed Web of Science ®Google Scholar
• Giles GI , JacobC. Reactive sulfur species: an emerging concept in oxidative stress. J. Biol. Chem.383(383), 375–388 (2002).
   Google Scholar
• Vajragupta O , BoonchoongPberliner LJ. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. Free Radical Res.38(3), 303–314 (2004).
   PubMed Web of Science ®Google Scholar
• Geier DA , KernJK, GarverCRet al. Biomarkers of environmental toxicity and susceptibility in autism. J. Neurol. Sci.280(1–2), 101–108 (2009).
   PubMedGoogle Scholar
• Vincent AM , RussellJW, LowP, FeldmanEL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev.25(4), 612–628 (2004).
   PubMed Web of Science ®Google Scholar
• Kador PF , KinoshitaJH, SharplessNE. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem.28(7), 841–849 (1985).
   PubMed Web of Science ®Google Scholar
• Oates PJ , MylariBL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Inv. Drug8(12), 2095–2119 (1999).
   PubMedGoogle Scholar
• Ramasamy R . Aldose reductase: a novel target for cardioprotective interventions. Curr. Drug Targets4(8), 625–632 (2003).
   PubMed Web of Science ®Google Scholar
• Dvornik D , Simard-DuquesneN, KramiMet al. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science182(4117), 1146–1148 (1973).
   PubMed Web of Science ®Google Scholar
• Kikkawa R , HatanakaI, YasudaHet al. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia24(4), 290–292 (1983).
   PubMed Web of Science ®Google Scholar
• Sestanj K , BelliniF, FungSet al. N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (tolrestat), a potent, orally active aldose reductase inhibitor. J. Med. Chem.27(3), 255–256 (1984).
   PubMed Web of Science ®Google Scholar
• Mylari BL , LarsonER, BeyerTAet al. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J. Med. Chem.34(1), 108–122 (1991).
   PubMed Web of Science ®Google Scholar
• Asano T , SaitoY, KawakamiM, YamadaN. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J. Diabetes Complicat.16(2), 133–138 (2002).
   PubMed Web of Science ®Google Scholar
• Van Zandt MC , JonesML, GunnDEet al. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J. Med. Chem.48(9), 3141–3152 (2005).
   PubMed Web of Science ®Google Scholar
• Tomlinson DR , StevensEJ, DiemelLT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol. Sci.15(8), 293–297 (1994).
   PubMed Web of Science ®Google Scholar
• Luca C , GiulioR, PaolaV, GiorgioC, DanielaB. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med. Res. Rev.19(1), 3–23 (1999).
   PubMed Web of Science ®Google Scholar
• Hayman S , KinoshitaJH. Isolation and properties of lens aldose reductase. J. Bio. Chem.240(2), 877–882 (1965).
   PubMed Web of Science ®Google Scholar
• Fukushi S , MerolaLO, KinoshitaJH. Altering the course of cataracts in diabetic rats. Invest. Ophth. Vis. Sci.19(3), 313–315 (1980).
   PubMed Web of Science ®Google Scholar
• Negoro T , MurataM, UedaSet al. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2’,3,5'-tetrone (AS-3201) and its congeners. J. Med. Chem.41(21), 4118–4129 (1998).
   PubMed Web of Science ®Google Scholar
• Giannoukakis N . Drug evaluation: ranirestat -- an aldose reductase inhibitor for the potential treatment of diabetic complications. Curr. Opin. Investig. Drugs7(10), 916–923 (2006).
   PubMed Web of Science ®Google Scholar
• Hamada DY , NakamuraJ. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat. Endocrinol.3(4), 245–255 (2004).
   PubMedGoogle Scholar
• Maccari R , OttanaR. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions. J. Med. Chem.58(5), 2047–2067 (2015).
   PubMed Web of Science ®Google Scholar
• Mylari BL , ArmentoSJ, BeebeDAet al. A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one. J. Med. Chem.46(12), 2283–2286 (2003).
   PubMed Web of Science ®Google Scholar
• Alexiou P , NicolaouI, StefekM, KristlA, DemopoulosVJ. Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. Bioorg. Med. Chem.16(7), 3926–3932 (2008).
   PubMed Web of Science ®Google Scholar
• Chatzopoulou M , MamadouE, JuskovaMet al. Structure–activity relations on [1-(3,5-difluoro-4-hydroxyphenyl)-1 H -pyrrol-3-yl]phenylmethanone. The effect of methoxy substitution on aldose reductase inhibitory activity and selectivity. Bioorg. Med. Chem.19(4), 1426–1433 (2011).
   PubMed Web of Science ®Google Scholar
• Papastavrou N , ChatzopoulouM, PegklidouK, NicolaouI. 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors. Bioorg. Med. Chem.21(17), 4951–4957 (2013).
   PubMed Web of Science ®Google Scholar
• Maccari R , VitaleRM, OttanàRet al. Structure–activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents. Eur. J. Med. Chem81C(81C), 1–14 (2014).
   Google Scholar
• Bohren KM , GrimshawCE, GabbayKH. Catalytic effectiveness of human aldose reductase. Critical role of C-terminal domain. J. Biol. Chem.267(29), 20965–20970 (1992).
   PubMed Web of Science ®Google Scholar
• El-Kabbani O , WilsonDK, PetrashM, QuiochoFA. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol. Vis.4(4), 19 (1998).
   PubMedGoogle Scholar
• Barski OA , GabbayKH, BohrenKM. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry35(45), 14276–14280 (1996).
   PubMed Web of Science ®Google Scholar
• Urzhumtsev A , Tête-FavierF, MitschlerAet al. A ‘specificity’ pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure5(5), 601–612 (1997).
   PubMed Web of Science ®Google Scholar
• Feather MS , FlynnTG, MunroKA, KubiseskiTJ, WaltonDJ. Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase. Biochim. Biophys. Acta1244(1), 10–16 (1995).
   PubMed Web of Science ®Google Scholar
• Yang Y , ZhangS, WuBet al. An efficient synthesis of quinoxalinone derivatives as potent inhibitors of aldose reductase. ChemMedChem7(5), 823–835 (2012).
   PubMed Web of Science ®Google Scholar
• Hussain S , ParveenS, HaoXet al. Structure-activity relationships studies of quinoxalinone derivatives as aldose reductase inhibitors. Eur. J. Med. Chem.80, 383–392 (2014).
   PubMed Web of Science ®Google Scholar
• Hao X , QinX, HussainSet al. Chiral resolution, determination of absolute configuration, and biological evaluation of (1,2-benzothiazin-4-yl)acetic acid enantiomers as aldose reductase inhibitors. J. Enzyme. Inhib. Med. Chem.30(5), 846–851 (2015).
   PubMed Web of Science ®Google Scholar
• Qin X , HaoX, HanHet al. Design and synthesis of potent and multifunctional aldose reductase inhibitors based on quinoxalinones. J. Med. Chem.58(3), 1254–1267 (2015).
   PubMed Web of Science ®Google Scholar
• Zou Y , QinX, HaoXet al. Phenolic 4-hydroxy and 3,5-dihydroxy derivatives of 3-phenoxyquinoxalin-2(1H)-one as potent aldose reductase inhibitors with antioxidant activity. Bioorg. Med. Chem. Lett.25(18), 3924–3927 (2015).
   PubMed Web of Science ®Google Scholar
• Han Z , HaoX, MaB, ZhuC. A series of pyrido[2,3-b]pyrazin-3(4H)-one derivatives as aldose reductase inhibitors with antioxidant activity. Eur. J. Med. Chem121, 308–317 (2016).
   PubMed Web of Science ®Google Scholar
• Felding J , KristensenJ, BjerregaardT, SanderL, Veds⊘P, BegtrupM. Synthesis of 4-substituted 1-(benzyloxy)pyrazoles via iodine−magnesium exchange of 1-(benzyloxy)-4-iodopyrazole. J. Org. Chem.64(11), 4196–4198 (1999).
   Web of Science ®Google Scholar
• Azzam R , BorggraeveRD, CompernolleW, HoornaertF. Expanding the substitution pattern of 2(1H)-pyrazinones via Suzuki and Heck reactions. Cheminform61(16), 3953–3962 (2005).
   Google Scholar
• Wang M , ZhangZ, XieF, ZhangW. Cu-catalyzed amidation of halogenated imidazoles. Chem. Commun.50(24), 3163–3165 (2014).
   PubMed Web of Science ®Google Scholar
• Concettina LM , StefaniaS, LauraMet al. Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity. J. Med. Chem.50(20), 4917–4927 (2007).
   PubMed Web of Science ®Google Scholar
• Blois MS . Antioxidant determinations by the use of a stable free radical. Nature181(4617), 1199–1200 (1958).
   Web of Science ®Google Scholar
• Polyxeni A , DemopoulosVJ. A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity. J. Med. Chem.53(21), 7756 (2010).
   PubMed Web of Science ®Google Scholar
• El-Kabbani O , CarboneV, DarmaninCet al. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. J. Med. Chem.48(17), 5536–5542 (2005).
   PubMed Web of Science ®Google Scholar